Interruption of first trimester human pregnancy following Epostane therapy. Effect of prostaglandin E2 pessaries.
The effect of Epostane, a competitive inhibitor of the 3 beta hydroxy steroid dehydrogenase enzyme system in combination with prostaglandin E2 (PGE2) for induction of abortion in early first trimester pregnancy has been studied in a group of 20 women awaiting termination of pregnancy. The women were consecutively assigned to four treatment groups. The first group was treated with PGE2 alone, administered vaginally as a lipid based (Witepsol) pessary. The remaining three groups received Epostane at differing doses for 5 days, and were treated with PGE2 on the fourth day. Significant falls in serum progesterone and oestradiol occurred in the Epostane-treated patients. Abortion was induced in one of the five control patients and in three of 10 patients treated with low doses (300-400 mg) of Epostane. Intrauterine pressure monitoring showed an increased reactivity to PGE2 in the treated groups. At the highest dose (600 mg) of Epostane, serum progesterone and oestradiol showed the greatest decline to 8% and 21% of the pretreatment values, a prompt and sustained pressure response occurred to PGE2 and abortion was induced in all five patients. A critical degree of progesterone suppression appears to sensitize the myometrium to exogenous prostaglandin. This combined treatment is an effective method of early pregnancy termination and may have a role in the management of mid-trimester abortion.
D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors*; D000032:Abortion, Therapeutic; D000293:Adolescent; D000328:Adult; D000737:Androstenols / Q000627:therapeutic use*; D015232:Dinoprostone; D004357:Drug Synergism; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D009215:Myometrium / Q000187:drug effects*; D010570:Pessaries; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000097:blood; D011458:Prostaglandins E / Q000627:therapeutic use*; D014590:Uterine Contraction / Q000187:drug effects*
D000737:Androstenols; D011458:Prostaglandins E; D011374:Progesterone; D004958:Estradiol; C046855:epostane; D015096:3-Hydroxysteroid Dehydrogenases; D015232:Dinoprostone